Latest & greatest articles for latanoprost

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on latanoprost or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on latanoprost and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for latanoprost

21. Travoprost versus latanoprost combinations in glaucoma: economic evaluation based on visual field deficit progression

Travoprost versus latanoprost combinations in glaucoma: economic evaluation based on visual field deficit progression Travoprost versus latanoprost combinations in glaucoma: economic evaluation based on visual field deficit progression Travoprost versus latanoprost combinations in glaucoma: economic evaluation based on visual field deficit progression Schmier J K, Halpern M T, Covert D W, Robin A L Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined two treatments for patients with primary open-angle glaucoma or ocular hypertension. Treatment was a fixed combination of latanoprost 0.005%/timolol 0.5% (L/T) or a fixed combination of travoprost 0.004%/timolol 0.5% (T/T). Type of intervention Treatment. Economic

NHS Economic Evaluation Database.2006

22. Cost-effectiveness and cost-utility analysis of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom

Cost-effectiveness and cost-utility analysis of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom Cost-effectiveness and cost-utility analysis of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom Cost-effectiveness and cost-utility analysis (...) of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom Le Pen C, Ligier M, Berdeaux G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn

NHS Economic Evaluation Database.2005

23. A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension

A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension Day D G, Schacknow P N, Sharpe E D, Ellyn J C, Kulze J C, Threlkeld A B (...) , Jones E D, Brown R H, Jenkins J N, Stewart W C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology This study compared monotherapy with latanoprost 0.005%, bimatoprost 0.03% or topical beta-blockers for the treatment of open-angle

NHS Economic Evaluation Database.2004

24. A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension

A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension Walt J G, Lee J T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of bimatoprost 0.03% QD (BIM) and latanoprost 0.005% QD (LAT) in patients with glaucoma or ocular hypertension (OHT). The drugs were administered into both eyes once daily, in the evening. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population

NHS Economic Evaluation Database.2004

25. Latanoprost (Xalatan)

Latanoprost (Xalatan) Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6997 Fax 0141 248 3778 E-mail jmitchell@htbs.org.uk Chairman Professor David Lawson Scottish Medicines Consortium latanoprost (Xalatan) (No. 102/04) Pfizer Summary of Recommendation 12 July 2004 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows: ADVICE (...) : following a full submission. Latanoprost (Xalatan ® ) is accepted for restricted use within NHS Scotland for the treatment of raised intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. Use of latanoprost, as monotherapy, should be restricted to patients who have contraindications to beta-blockers or have a history of adverse reactions to this group of drugs. It may also be indicated in addition to beta-blockers when required. It is one of a number of topical ocular

Scottish Medicines Consortium2004

26. An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension

An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular (...) hypertension Stewart W C, Leech J, Sharpe E D, Kulze J, Ellyn J, Day D G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The authors investigated a switch to latanoprost monotherapy, or the addition of latanoprost or brimonidine

NHS Economic Evaluation Database.2002

27. Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects

Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects Halpern M T, Covert D W, Robin A L Record Status This is a critical (...) 100% of the medical visits, in 50% to less than 75% of the visits, or in less than 50% of the visits. The probability of VFD progression was assessed according to the IOP level of the patients, as reported by four different studies. The mean IOP was assessed overall, at baseline and throughout the day, during a 1-year study period for the treatments considered at analysis (travoprost, latanoprost and timolol), as reported by one RCT included in the review. These primary outcomes were included

NHS Economic Evaluation Database.2002

28. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension

Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension Zhang W Y, Po A L, Dua H (...) S, Azuara-Blanco A Authors' objectives To evaluate the efficacy and tolerance of latanoprost in comparison with timolol for open angle glaucoma and ocular hypertension. Searching MEDLINE, EMBASE and the Science Citation Index were searched from 1966 to July 2000. The search terms and strategies were described in the report. The bibliographies of studies and reviews were checked. The manufacturers' databases, including the Pharmacia Upjohn ophthalmology database and the Merck glaucoma database

DARE.2001

29. Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma

Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma Einarson T R, Kulin N A, Tingey D, Iskedjian M Authors' objectives To indirectly quantify and compare the intraocular pressure (IOP)- lowering effects (...) of latanoprost and brimonidine eye drops at baseline and after 3 and 6 months in the treatment of primary open-angle glaucoma. Searching The authors searched MEDLINE and EMBASE (1992 to May 1999) using the search terms 'ophthalmic', 'glaucoma', 'clinical trial', and either 'latanoprost' or 'brimonidine'. References from the retrieved articles were searched for additional studies. The search was restricted to English language publications. Study selection Study designs of evaluations included in the review

DARE.2000